Usefulness of Stereotactic Radiotherapy Using the CyberKnife for Patients with Inoperable Locoregional Recurrences of Differentiated Thyroid Cancer.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
30
9
2018
medline:
27
6
2019
entrez:
30
9
2018
Statut:
ppublish
Résumé
Surgical resection is the preferred treatment for locoregional recurrence of differentiated thyroid cancer (DTC). However, some recurrences are unresectable because of their aggressive invasion or severe adhesions. On the other hand, stereotactic radiotherapy (SRT) enables high-dose irradiation to target lesions, and its usefulness for various cancers has been reported. The objective of the present study was to investigate the feasibility and efficacy of SRT as salvage treatment for locoregional recurrence of DTC. Between August 2011 and December 2017, 52 locoregional recurrent lesions in 31 patients with recurrent DTC were treated by SRT using the CyberKnife system. Information on the adverse events associated with SRT was retrospectively collected from the patients' medical records. Of the 52 lesions, 33 could be evaluated for therapeutic effectiveness by follow-up CT, and response was assessed using the RECIST criteria. Twenty-five patients had papillary carcinoma, 5 had follicular carcinoma, and 1 had poorly differentiated cancer. SRT was delivered in one to 20 fractions, and the median dose was 30 Gy (range 15-60 Gy). Adverse events were not frequent, but 1 patient developed bilateral vocal cord palsy that required emergent tracheostomy. The median follow-up period of 33 lesions was 14 months (range 1-54 months). Complete response, partial response, stable disease, and progressive disease were seen in 10, 11, 9, and 3 patients, respectively. The 3-year local control rate was 84.6%. SRT using the CyberKnife system was found to be a feasible and effective treatment to suppress the growth of locoregional recurrence of DTC.
Sections du résumé
BACKGROUND
BACKGROUND
Surgical resection is the preferred treatment for locoregional recurrence of differentiated thyroid cancer (DTC). However, some recurrences are unresectable because of their aggressive invasion or severe adhesions. On the other hand, stereotactic radiotherapy (SRT) enables high-dose irradiation to target lesions, and its usefulness for various cancers has been reported. The objective of the present study was to investigate the feasibility and efficacy of SRT as salvage treatment for locoregional recurrence of DTC.
METHODS
METHODS
Between August 2011 and December 2017, 52 locoregional recurrent lesions in 31 patients with recurrent DTC were treated by SRT using the CyberKnife system. Information on the adverse events associated with SRT was retrospectively collected from the patients' medical records. Of the 52 lesions, 33 could be evaluated for therapeutic effectiveness by follow-up CT, and response was assessed using the RECIST criteria.
RESULTS
RESULTS
Twenty-five patients had papillary carcinoma, 5 had follicular carcinoma, and 1 had poorly differentiated cancer. SRT was delivered in one to 20 fractions, and the median dose was 30 Gy (range 15-60 Gy). Adverse events were not frequent, but 1 patient developed bilateral vocal cord palsy that required emergent tracheostomy. The median follow-up period of 33 lesions was 14 months (range 1-54 months). Complete response, partial response, stable disease, and progressive disease were seen in 10, 11, 9, and 3 patients, respectively. The 3-year local control rate was 84.6%.
CONCLUSION
CONCLUSIONS
SRT using the CyberKnife system was found to be a feasible and effective treatment to suppress the growth of locoregional recurrence of DTC.
Identifiants
pubmed: 30267291
doi: 10.1007/s00268-018-4813-5
pii: 10.1007/s00268-018-4813-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-518Références
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):795-801
pubmed: 18676097
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8
pubmed: 18755555
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1083-91
pubmed: 19095376
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2009 Apr 1;27(10):1579-84
pubmed: 19255320
J Clin Oncol. 2009 Jul 10;27(20):3290-6
pubmed: 19414667
Otolaryngol Head Neck Surg. 2010 Mar;142(3):338-43
pubmed: 20172377
J Clin Oncol. 2012 Jan 10;30(2):134-41
pubmed: 22025146
J Clin Oncol. 2013 Oct 10;31(29):3639-46
pubmed: 24002501
Endocrine. 2014 Nov;47(2):648-51
pubmed: 24610207
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Eur Radiol. 2015 Jan;25(1):163-70
pubmed: 25199815
Int J Hyperthermia. 2015 Jun;31(4):403-8
pubmed: 25792224
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109
pubmed: 27548104
Med Sci Monit. 2016 Dec 15;22:4924-4928
pubmed: 27974741
Case Rep Endocrinol. 2017;2017:7956726
pubmed: 28396808
Strahlenther Onkol. 2017 Jul;193(7):525-533
pubmed: 28424840
Endocr J. 2017 Aug 30;64(8):819-826
pubmed: 28659544